TerminatedEarly Phase 1

COVID-19 Vaccination in Rheumatic Disease Patients

Stopped: Difficulty with enrollment

United States58 participantsStarted 2021-02-15

Plain-language summary

The research is being done to study the immune responses to COVID-19 vaccination in patients with rheumatic diseases.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Rheumatologist confirmed diagnosis of one of the following diagnoses: * Systemic lupus erythematosus; * Sjogren syndrome; * Inflammatory myositis; * Psoriatic arthritis; * Osteoarthritis; * Gout; * Ankylosing spondylitis; * IBD-related arthritis. Exclusion Criteria: * Active infection or untreated malignancy (other than skin cancer) at enrollment. * Pregnancy

What they're measuring

Humoral responses towards mRNA COVID-19 vaccines

Timeframe: 2 weeks to 6 months after second dose of vaccine

Trial details

NCT IDNCT04839315

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-02-09

View on ClinicalTrials.gov More Systemic Lupus Erythematosus trials